Skip to main content
Wolfson Institute of Population Health

Dr Peter MacCallum

Peter

Clinical Reader in Haematology

Email: p.k.maccallum@qmul.ac.uk
Telephone: +44 (0) 20 7882 6203

Profile

Peter MacCallum is senior lecturer in haematology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London, and honorary consultant haematologist at Barts Health NHS Trust, London, where he has served as Head of clinical and laboratory haematology since 2004. He has been clinical lead for thrombosis and anticoagulant services since 1996. He qualified in medicine from the University of Sheffield and trained in haematology in Manchester and London. He was an MRC Clinical Fellow based at St Batholomew's School of Medicine prior to appointment to his current post in 1995. 
He has held the position of Principal Investigator in a number of trials of the new oral anticoagulants for stroke prevention in atrial fibrillation and in the management of venous thromboembolism, and is Chief Investigator of a UK-wide study examining outcomes of major bleeding in anticoagulated patients (ORANGE study). He is also the UK Chief Investigator for GARFIELD-VTE, a global cohort study of the long-term outcomes of patients with newly diagnosed venous thromboembolism.
He has been a reviewer for the National Institute of Clinical Excellence (NICE) clinical guidelines and has served an a specialist member of both the NICE Diagnostic Advisory Committee and the NICE Technology Appraisal Committee. He has co-authored national guidelines for the Royal College of Obstetricians and Gynaecologists on the prevention of venous thromboembolism in pregnancy and the puerperium. He has had numerous papers published in the field of thrombosis, including research into the epidemiology of travel-related thrombosis, thrombotic markers of pregnancy-related problems, and the importance of fibrinolytic activation in trauma patients.

Research

Research Interests:

  • E-Cigarette & Nicotine Inhalator on tobacco withdraval symptons
  • ORANGE Study

Publications

    • Cohen AT, Lewis M, Connor A et al. (2022), Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. $nameOfConference


    • Cohen O, Ageno W, Farjat AE et al. (2022), Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE $nameOfConference


    • Weitz JI, Farjat AE, Ageno W et al. (2021), Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE $nameOfConference


    • Platton S, Bartlett A, MacCallum P et al. (2021), Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination $nameOfConference


    • Goto S, Turpie AGG, Farjat AE et al. (2021), The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE $nameOfConference


    • Makariou N, Mills S, Bariana T et al. (2021), Virtual clinics - the future of thrombosis and anticoagulant consultations? A patient preference survey. $nameOfConference

    • Jerjes-Sánchez C, Rodriguez D, Farjat AE et al. (2021), Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. $nameOfConference


    • Platton S, Schönborn L, Charrot S et al. (2021), Vaccine-induced immune thrombocytopenia and thrombosis: The decline in anti-platelet factor 4 antibodies is assay-dependent $nameOfConference


    • Tan J, Maccallum P, Curry N et al. (publicationYear), Correction of International Normalised Ratio in major bleeding related to vitamin K antagonists is associated with better survival: a UK study $nameOfConference


    • Weitz JI, Haas S, Ageno W et al. (2020), Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE $nameOfConference


    • Bowles L, Platton S, Yartey N et al. (2020), Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. $nameOfConference


    • Kohli R, Estcourt L, Zaidi A et al. (2020), Efficacy and safety of chemical thromboprophylaxis in renal transplantation – A systematic review $nameOfConference


    • Kohli R, Estcourt L, Zaidi A et al. (2020), A systematic review of efficacy and safety of chemical thromboprophylaxis in renal transplantation $nameOfConference

    • Haywood M, Bowles L, Platton S et al. (2020), Heparin-induced thrombocytopaenia (HIT): an audit of the diagnostic pathway at Barts Health NHS Trust $nameOfConference

    • Poynton M, Hibbs S, MacCallum P et al. (2020), Incidence and management of PEGylated-asparaginase related thrombosis in adults with ALL $nameOfConference

    • Todd S, Sivapathasuntharam D, Bowles L et al. (2020), Management of traumatic intracranial haemorrhage in elderly patients on anticoagulation: a trauma centre experience $nameOfConference

    • MacCallum PK, Bowles L (2020), Thrombosis in pregnancy $nameOfConference


    • Chahal JK, Antoniou S, Earley M et al. (2019), Preventing strokes in people with atrial fibrillation by improving ABC. $nameOfConference


    • Green L, Tan J, Antoniou S et al. (2019), Haematological management of major bleeding associated with direct oral anticoagulants – UK experience $nameOfConference


    • Kohli R, Forbes S, Thuraisingham R et al. (2019), Survey of thromboprophylaxis strategies in renal transplant recipients at a single transplant unit $nameOfConference

    • Carroll R, Mansell J, Platton S et al. (2018), The Future of Activated Clotting Time? $nameOfConference


    • Young AM, Marshall A, Thirlwall J et al. (2018), Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). $nameOfConference


    • Green L, Tan J, Morris JK et al. (2018), A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the uk (Orange study) $nameOfConference


    • Platton S, Bowles L, MacCallum P (2017), Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents $nameOfConference


    • Green L, Tan J, Grist C et al. (2017), Aetiology and outcome of massive transfusion in two large London teaching hospitals over a 3-year period (2012–2014) $nameOfConference


    • Collins J, Bowles L, MacCallum PK (2016), Prevention and management of venous thromboembolism in pregnancy $nameOfConference


    • Chahal J, MacCallum P, Wright P et al. (2016), Antiphospholipid syndrome: Pathophysiology, diagnosis and treatment $nameOfConference


    • Collins J, Greinacher A, MacCallum P (2016), Autoimmune heparin-induced thrombocytopenia: A case report $nameOfConference

    • Platton SJM, Bowles L, MacCallum PK (2016), Dilute Russell's viper venom time - potential use for the detection of apixaban and rivaroxaban predicted from interference in lupus anticoagulant testing $nameOfConference

    • Platton SJM, Bowles L, MacCallum PK (2016), Effects of rivaroxaban and apixaban on routine coagulation screening tests $nameOfConference

    • Tait CR, Morris JK, Tan J et al. (2016), Trends in oral anticoagulant prescriptions and major bleeding complications: A comparison of NHS CCG prescription data with cases from a prospective study (ORANGE) between October 2013 and June 2015 $nameOfConference

    • Renukanthan A, Quinton R, Turner B et al. (2015), Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia $nameOfConference


    • Badle S, Coppack S, MacCallum P (2015), Thromboprophylaxis in a patient with morbid obesity $nameOfConference

    • Kalkur P, Kreze O, Chauhan N et al. (2015), Direct oral anti-coagulants for prevention of stroke and systemic embolism in non-valvular atrial fibrillation - Barts Health experience across two sites $nameOfConference

    • Green L, Morris J, Alikhan R et al. (2015), Oral anticoagulant agent-associated bleeding events reporting system (ORANGE) study $nameOfConference

    • Frise CJ, MacCallum PK, Mackillop LH et al. (2015), Systemic Thromboembolism in Pregnancy: Thromboprophylaxis $nameOfConference


    • Green L, Alikhan R, Curry N et al. (2014), Oral anticoagulant agent-associated bleeding events reporting system (ORANGE) study. $nameOfConference


    • MacCallum P, Bowles L, Keeling D (2014), Diagnosis and management of heritable thrombophilias. $nameOfConference


    • Dadgar M, Pickford G, MacCallum P et al. (2014), PWE-080 Beware The Interaction Between Thiopurines And Warfarin. $nameOfConference


    • Sinha S, Hossain U, MacCallum P (2014), SCREENING FOR MALIGNANCY IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM $nameOfConference

    • Robson J, Dostal I, Mathur R et al. (2014), Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts. $nameOfConference


    • Rahiminejad M, Rastogi A, Prabhudesai S et al. (2014), Evaluating the Use of a Negative D-Dimer and Modified Low Wells Score in Excluding above Knee Deep Venous Thrombosis in an Outpatient Population, Assessing Need for Diagnostic Ultrasound. $nameOfConference


    • Maccallum PK, Mathur R, Hull SA et al. (2013), Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. $nameOfConference


    • Platton SJ, Nahar B, Dale C et al. (2013), False-positive results for a lupus anticoagulants occur in patients on low molecular weight heparin but not fondaparinux, by dilute activated partial thromboplastin time $nameOfConference

    • MacCallum PK, Mathur R, Hull SA et al. (2013), Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation $nameOfConference


    • Van der Krogt L, Barber C, MacCallum P et al. (2013), Retrospective study of the Massive Haemorrhage Protocol adherence in the management of trauma-induced bleeding at the Royal London Hospital $nameOfConference

    • MacCallum PK (2013), COPD and thrombosis $nameOfConference


    • Raza I, Davenport R, Rourke C et al. (2013), The incidence and magnitude of fibrinolytic activation in trauma patients. $nameOfConference


    • Mpouzouki A, Bowles L, Beski S et al. (2013), A retrospective review of risk factors for thrombosis in women presenting with venous thromboembolism (VTE) during pregnancy and the puerperium $nameOfConference


    • Frise CJ, MacCallum PK, Mackillop LH et al. (2012), Systemic Thromboembolism in Pregnancy: Thromboprophylaxis $nameOfConference


    • Kint M, Platton S, Hart D et al. (2012), A retrospective study of thrombophilia testing requests in a large teaching hospital $nameOfConference


    • Pandya J, Islam A, MacCallum P et al. (2012), A single-centre retrospective study of prothrombin complex concentrate (octaplex) use $nameOfConference

    • Verghese L, Alam S, Beski S et al. (2012), Antenatal screening for pre-eclampsia: evaluation of the NICE and pre-eclampsia community guidelines. $nameOfConference


    • Provan D, Newland AC, MacCallum PK (2011), Acquired disorders affecting megakaryocytes and platelets $nameOfConference


    • MacCallum PK, Ashby D, Hennessy EM et al. (2011), Cumulative flying time and risk of venous thromboembolism. $nameOfConference


    • Davenport R, Manson J, De'Ath H et al. (2011), Functional definition and characterization of acute traumatic coagulopathy. $nameOfConference


    • Agarwal N, Deinde O, Willmott F et al. (2011), A case series of interventional radiology in postpartum haemorrhage. $nameOfConference


    • Prabhudesai SG, Rastogi A, Platton S et al. (2011), Evaluating the use of negative D-Dimer and low wells score in excluding above knee deep venous thrombosis in an outpatient population at a major London teaching hospital $nameOfConference

    • Varma G, Mills S, Gutteridge C et al. (2011), Implementation of a venous thromboembolism (VTE) risk assessment tool to improve inpatient thromboprophylaxis $nameOfConference

    • Raza I, Davenport R, Rourke C et al. (2011), Occult activation of fibrinolysis in trauma $nameOfConference

    • Uprichard J, Boomla K, Mills S et al. (2011), The incidence of venous thromboembolism (VTE) in East London $nameOfConference

    • Davenport R, Manson J, De'Ath H et al. (2011), Point of care diagnostics for the rapid identification of acute traumatic coagulopathy and prediction of massive trauma haemorrhage $nameOfConference

    • Uprichard J, Boomla K, Mills S et al. (2011), The incidence of venous thromboembolism (VTE) in East London $nameOfConference

    • Uprichard J, Mills S, MacCallum PK et al. (2011), The use of an electronic patient record to improve patient safety for anticoagulation $nameOfConference

    • Posner C, Owen M, Melhem N et al. (2010), An acutely swollen leg $nameOfConference


    • Rao AP, Bojahr H, Beski S et al. (2010), Role of interventional radiology in the management of morbidly adherent placenta $nameOfConference


    • Rudnicka AR, MacCallum PK, Whitelocke R et al. (2010), Circulating markers of arterial thrombosis and late-stage age-related macular degeneration: a case-control study. $nameOfConference


    • Coleman R, MacCallum P (2010), Treatment and secondary prevention of venous thromboembolism in cancer $nameOfConference


    • Saha A, Nguyen T, Watson C et al. (2010), The implementation of a simple step-wise intervention which dramatically improved the thromboprophylaxis rate in medical cancer patients $nameOfConference


    • Macey MG, Bevan S, Alam S et al. (2010), Platelet activation and endogenous thrombin potential in pre-eclampsia. $nameOfConference


    • Donaldson GC, Seemungal TA, Patel IS et al. (2009), Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. $nameOfConference


    • Meade TW, MacCallum PK (2009), Coagulation, thrombosis, and coronary heart disease $nameOfConference


    • Truss NJ, Beavis J, Maccallum PK et al. (2009), Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96-well microtiter plates $nameOfConference


    • Poller L, Keown M, Ibrahim S et al. (2009), A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program $nameOfConference


    • Hogg M, MacCallum P, Beski S (2009), Angiomyolipoma with renal vein thrombosis in pregnancy: a case report and review of the literature $nameOfConference


    • Rudnicka AR, MacCallum PK, Whitelocke R et al. (2009), Circulating markers of arterial thrombosis and age-related maculopathy: a case-control study $nameOfConference

    • Greaves P, Madhani M, Hallam S et al. (2009), Off-license use of recombinant factor VIIa: a single centre experience $nameOfConference

    • Davenport R, Coates A, Allard S et al. (2009), TRAUMA HAEMORRHAGE: EVOLVING ROLE OF ROTEM FOR PREDICTING TRANSFUSION REQUIREMENTS $nameOfConference

    • Poller L, Keown M, Ibrahim S et al. (2008), An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage $nameOfConference


    • Madhani M, Pasi KJ, Gutteridge CN et al. (2008), Preventing venous thromboembolism (VTE) in hospitalised patients: putting guidance into practice $nameOfConference

    • MacCallum P, Madhani M, Mt-Isa S et al. (2007), Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. $nameOfConference


    • Coats TJ, Brazil E, Heron M et al. (2006), Impairment of coagulation by commonly used resuscitation fluids in human volunteers $nameOfConference


    • Akinwunmi F, Engova D, Duggan C et al. (2006), Patient satisfaction as an anticoagulation service development tool $nameOfConference

    • MacCallum PK, Hennessey EM, Beski S (2006), Incidence of pregnancy-associated venous thromboembolism. $nameOfConference


    • Donaldson GC, Seemungal TA, Patel IS et al. (2006), Airway and systemic inflammation and decline in lung function in patients with COPD Chest 2005;128:1995–2004 $nameOfConference


    • Gauthaman N, Holden E, Mandana R et al. (2006), Clinical outcome of high risk patients on enoxaparin during the antenatal period - a prospective study. $nameOfConference

    • MACCALLUM PK, Madhani M (2006), Managing VTE $nameOfConference

    • Donaldson GC, Seemungal TAR, Patel IS et al. (2005), Airway and systemic inflammation and decline in lung function in patients with COPD. $nameOfConference


    • MacCallum PK (2005), Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. $nameOfConference


    • MacCallum PK, Rudnicka AR, Rumley A et al. (2004), Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction $nameOfConference


    • Engova D, Duggan C, MacCallum P (2004), The role of medication adherence in warfarin anticoagulation control and its cognitive determinants $nameOfConference

    • MacCallum PK, Cooper JA, Rumley A et al. (2004), Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. $nameOfConference


    • Hill AS, MacCallum PK, Young BD et al. (2003), Molecular cloning of a constitutional t(7;22) translocation associated with risk of hematological malignancy. $nameOfConference


    • Bowles LK, Cooper JA, Howarth DJ et al. (2003), Associations of haemostatic variables with body mass index: a community-based study. $nameOfConference


    • MacCallum PK, Rudnicka AR, Rumley A et al. (2003), Low-intensity warfarin reduces thrombin generation and fibrin turnover without affecting inflammation $nameOfConference

    • Kennon S, Price CP, Mills PG et al. (2003), Cumulative risk assessment in unstable angina: clinical, electrocardiographic, autonomic, and biochemical markers. $nameOfConference


    • MACCALLUM PK, Miller GJ, Meade TW (2003), The haemostatic system in arterial disease. $nameOfConference

    • Seemungal TAR, Wedzicha JA, MacCallum PK et al. (2002), Chlamydia pneumoniae and COPD exacerbation. $nameOfConference


    • Engova D, Duggan C, Shearer M et al. (2002), Effects of age and cytochrome P450 polymorphism on the maintenance dose of warfarin. $nameOfConference

    • Jamshidi Y, Flavell DM, Hawe E et al. (2002), Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. $nameOfConference


    • Gale CR, Ashurst HE, Hall NF et al. (2002), Size at birth and carotid atherosclerosis in later life $nameOfConference


    • MACCALLUM PK (2002), Anticoagulant therapy following oral anticoagulant treatment for VTE. $nameOfConference

    • Seemungal T, Harper-Owen R, Bhowmik A et al. (2001), Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. $nameOfConference


    • MacCallum PK, Brennan PJ, Meade TW (2001), Minimum intensity anticoagulation therapy as primary prevention strategy - In reply $nameOfConference


    • Rohatiner AZS, LISTER TA, Dalley CD et al. (2001), Acute myelogenous leukaemia in patients 60 years and older, a retrospective analysis from St. Bartholomew's Hospital 1969-1999. $nameOfConference


    • MacCallum P (2001), Book Review. $nameOfConference


    • MACCALLUM PK, Cavenagh J, Thomas JM et al. (2001), Optimising testing for phospholipid antibodies. $nameOfConference


    • MACCALLUM PK, Barlow C, Edwards MJ et al. (2001), Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. $nameOfConference


    • MacCallum PK, Brennan PJ, Meade TW (2000), Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease $nameOfConference


    • Wedzicha JA, Seemungal TAR, MacCallum PK et al. (2000), Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels $nameOfConference


    • MacCallum PK, Cooper JA, Martin J et al. (2000), Haemostatic and lipid determinants at prothrombin fragment F1.2 and D-dimer in plasma $nameOfConference


    • Kennon S, Barakat K, Suliman A et al. (2000), Influence of previous aspirin treatment and smoking on the electrocardiographic manifestations of injury in acute myocardial infarction $nameOfConference


    • Roland MA, Seemungal TAR, Bhowmik A et al. (1999), P17 Effect of exacerbation on plasma levels of tissue factor in patients with COPD $nameOfConference


    • MacCallum PK, Meade TW (1999), Haemostatic function, arterial disease and the prevention of arterial thrombosis $nameOfConference


    • MacCallum PK, Meade TW (1999), Preface $nameOfConference


    • Kennon S, Suliman A, MacCallum PK et al. (1998), Clinical characteristics determining the mode of presentation in patients with acute coronary syndromes $nameOfConference


    • Seemungal T, MacCallum P, Wedzicha JA (1998), Plasma fibrinogen is a marker of COPD exacerbation $nameOfConference

    • Poller L, Shiach CR, MacCallum PK et al. (1998), Multicentre randomised study of computerised anticoagulant dosage $nameOfConference


    • Maccallum PK, Cooper JA, Martin J et al. (1998), Associations of protein C and protein S with serum lipid concentrations $nameOfConference


    • MacCallum PK, Cooper JA, Howarth DJ et al. (1998), Sex differences in the determinants of fibrinolytic activity $nameOfConference


    • MacCallum PK, Cooper JA, Meade TW et al. (1996), P26. Comparison of associations of prothrombin fragment F1.2 and D-dimer in a healthy population $nameOfConference


    • MacCallum PK, Cooper JA, Miller GJ et al. (1995), Determinants of the dilute clot lysis time (DCLT) in a healthy general practice-based population—the Harefield Study $nameOfConference


    • MacCallum PK, Rohatiner AZS, Davis CL et al. (1995), Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients $nameOfConference


    • MacCallum PK, Meade TW, Cooper JA et al. (1995), Clotting factor VIII and risk of deep-vein thrombosis $nameOfConference


    • Poller L, Thomson JM, MacCallum PK et al. (1995), Minidose Warfarin and Failure to Prevent Deep Vein Thrombosis After Joint Replacement Surgery Despite Inhibiting the Postoperative Rise in Plasminogen Activator Inhibitor Activity $nameOfConference


    • Banerjee P, Maccallum PK, Walker RWH et al. (1995), Polyradiculopathy complicating acute lymphoblastic leukemia $nameOfConference


    • Meade TW, Howarth DJ, Cooper J et al. (1994), Fibrinolytic activity and arterial disease $nameOfConference


    • Rohatiner AZS, Johnson PWM, Price CGA et al. (1994), Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma $nameOfConference


    • MacCallum PK, Davis CL, Rohatiner AZS et al. (1993), Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence $nameOfConference

    • Lillington DM, MacCallum PK, Lister TA et al. (1993), Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: Two cases and a review of the literature $nameOfConference

    • Slater SE, Maccallum PK, Birjandi F et al. (1992), Acute myelogenous leukemia (AML) and diabetes insipidus (DI): Further association with monosomy 7 $nameOfConference


    • Whelan JS, Davis CL, Rohatiner AZS et al. (1992), Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy $nameOfConference


    • Bassan R, Battista R, Rohatiner AZS et al. (1992), Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period $nameOfConference

    • Gibbons B, MacCallum P, Watts E et al. (1991), Near haploid acute lymphoblastic leukemia: Seven new cases and a review of the literature $nameOfConference

    • MacCallum PK, Thomson JM, Poller L (1990), Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery $nameOfConference


    • Poller L, MacCallum PK, Thomson JM et al. (1990), Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study $nameOfConference


    • MacCallum PK, Freemont AJ, Geary CG et al. (1988), A case of IgD myeloma presenting as diffuse osteosclerosis $nameOfConference


    • MacCallum PK, Newbould MJ, Sambrook PS et al. (1988), Extramedullary haemopoietic tumours complicating polycythaemia vera $nameOfConference


    • Smith SR, Auger MJ, Maccallum PK et al. (1987), HYPOTHYROIDISM AND VON WILLEBRAND'S DISEASE $nameOfConference


    • Benbow EW, Love EM, Love HG et al. (1987), Massive right atrial thrombus associated with a Chiari network and a Hickman catheter $nameOfConference


    • Gozzwar DI, MacCallum PK, Love EM (1986), Management of infection in the neutropenic patient $nameOfConference


Back to top